Join us at RAPS Euro Convergence 2024 on 6-8 May in Berlin, Germany
April 26, 2024EAEU GMP Certificate is Mandatory
All pharmaceutical companies operating in the EAEU market (Kazakhstan, Belarus, Russia, Armenia, Kyrgyzstan) have to obtain the EAEU GMP certificate.
The process of EAEU GMP inspection is a challenge for many international pharmaceutical companies. That is why it is highly recommended to be prepared for inspection in advance and to conduct pre-audit of the respective manufacturing site. This will identify the possible gaps regarding the EAEU GMP guidelines before the official inspection.
Inpharmatis has over 15 years of experience in conducting GMP pre-audits and successfully supporting global and local pharmaceutical companies with official GMP inspections. Additionally, Inpharmatis has full competence in supporting EAEU regulatory procedures.
Inpharmatis covers all EAEU countries with full-time, highly qualified, multilingual employees who operate under a global quality system.
For more information, please contact us at info@inpharmatis.com.
Полина Домбуре, директор Inpharmatis, приняла участие в ISPE Europe Annual Conference 2024
April 23, 2024Dr. Polina Dombure, Inpharmatis Group CEO, Participated in ISPE Europe Annual Conference 2024
April 23, 2024Трудности регистрации медицинских изделий в ЕАЭС
March 26, 2024Challenges of Medical Devices Registration in the EAEU
March 26, 2024Новые поправки к Федеральному закону "Об обращении лекарственных средств" в России
March 13, 2024New Amendments in Federal Law “On Circulation of Medicines” in Russia
March 13, 2024В Грузии фармацевтические компании, не предоставившие сертификат GMP, столкнулись с новыми рисками
February 28, 2024In Georgia, Pharmaceutical Companies That Have Not Provided a GMP Certificate are Facing New Risks
February 28, 2024Получение GMP сертификата ЕАЭС обязательная процедура
February 21, 2024